Sustained corticosteroid-sparing effects of upadacitinib maintenance therapy in patients with moderate-to-severe crohn’s disease: 2-year results from the U-ENDURE long-term extension study

Background: Long-term use of corticosteroids (CS) is a concern for patients (pts) with Crohn's disease (CD), as prolonged use is associated with increased mortality and adverse outcomes. Upadacitinib (UPA), an oral, selective, reversible JAK inhibitor, approved for moderate-to-severe CD, demonstrated CS-sparing efficacy with a consistent safety profile through maintenance week (wk) 52. [1] [2] [3] [4] We evaluated the long-term efficacy of UPA in achieving CS-free clinical and endoscopic outcomes in pts in the U-ENDURE long-term extension (LTE) study.